ONCOLOGY: February 2009 Volume 23 Number 2 Supplement 1

Article

Infusion Reactions Associated With Monoclonal Antibodies in Patients With Solid Tumors This supplement and associated publication costs were funded by Amgen

Infusion Reactions Associated With Monoclonal Antibodies in Patients With Solid Tumors
This supplement and associated publication costs were funded by Amgen


Infusion reactions are well-known in cancer treatment, occurring with both cytotoxic and biologic agents. The five articles presented in this supplement to ONCOLOGY cover a wide range of topics related to antibody-induced infusion reactions: immunologic mechanisms and risk factors; a focus on anaphylaxis; US and EU perspectives on the state of clinical trials; a health economic analysis of the burden on patients, caregivers, and providers; and a nursing perspective on infusion reaction management.
 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
4 experts in this video
2 experts in this video
Related Content
Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma

Nurulimab/Prolgolimab Yield Superior Efficacy in Advanced Melanoma

Ariana Pelosci
April 28th 2025
Article

The combination of nurulimab plus prolgolimab enhanced PFS, ORR, and DCR compared with prolgolimab monotherapy in unresectable or metastatic melanoma.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Same-Day G-CSF After Chemo Appears Safe, Efficacious in Breast Cancer

Roman Fabbricatore
April 28th 2025
Article

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Health Care Professional Research Highlights Barriers to Clinical Trial Diversity

Tim Cortese
April 28th 2025
Article
Radical Prostatectomy Linked to Lower GU Toxicity in Localized Prostate Cancer

Radical Prostatectomy Linked to Lower GU Toxicity in Localized Prostate Cancer

Ariana Pelosci
April 28th 2025
Article

Toxicity complications were assessed between single- and multiple-treatment modalities for patients with localized prostate cancer.